These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9700726)

  • 1. DNA binding activities of p53 protein following cisplatin damage of ovarian cells.
    Wetzel CC; Berberich SJ
    Oncol Res; 1998; 10(3):151-61. PubMed ID: 9700726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive mdmx expression during cell growth, differentiation, and DNA damage.
    Jackson MW; Berberich SJ
    DNA Cell Biol; 1999 Sep; 18(9):693-700. PubMed ID: 10492400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged wild-type p53 protein accumulation and cisplatin resistance.
    Yazlovitskaya EM; DeHaan RD; Persons DL
    Biochem Biophys Res Commun; 2001 May; 283(4):732-7. PubMed ID: 11350044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation.
    Mayo LD; Berberich SJ
    Oncogene; 1996 Dec; 13(11):2315-21. PubMed ID: 8957072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53.
    Mayo LD; Turchi JJ; Berberich SJ
    Cancer Res; 1997 Nov; 57(22):5013-6. PubMed ID: 9371494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
    Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
    Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 binds to cisplatin-damaged DNA.
    Wetzel CC; Berberich SJ
    Biochim Biophys Acta; 2001 Feb; 1517(3):392-7. PubMed ID: 11342217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
    Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis.
    Kondo S; Barnett GH; Hara H; Morimura T; Takeuchi J
    Oncogene; 1995 May; 10(10):2001-6. PubMed ID: 7761100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.
    Pestell KE; Medlow CJ; Titley JC; Kelland LR; Walton MI
    Int J Cancer; 1998 Sep; 77(6):913-8. PubMed ID: 9714063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mdm-2 gene is induced in response to UV light in a p53-dependent manner.
    Perry ME; Piette J; Zawadzki JA; Harvey D; Levine AJ
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11623-7. PubMed ID: 8265599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis.
    Kondo S; Barna BP; Kondo Y; Tanaka Y; Casey G; Liu J; Morimura T; Kaakaji R; Peterson JW; Werbel B; Barnett GH
    Oncogene; 1996 Sep; 13(6):1279-85. PubMed ID: 8808702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.
    Fajac A; Da Silva J; Ahomadegbe JC; Rateau JG; Bernaudin JF; Riou G; Bénard J
    Int J Cancer; 1996 Sep; 68(1):67-74. PubMed ID: 8895543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound.
    Sun Y; Bian J; Wang Y; Jacobs C
    Oncogene; 1997 Jan; 14(4):385-93. PubMed ID: 9053835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells.
    Bull EK; Chakrabarty S; Brodsky I; Haines DS
    Oncogene; 1998 Apr; 16(17):2249-57. PubMed ID: 9619834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
    Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
    Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.